Volume 18, Number 5—May 2012
Research
No Association between 2008–09 Influenza Vaccine and Influenza A(H1N1)pdm09 Virus Infection, Manitoba, Canada, 2009
Salaheddin M. Mahmud
, Paul Van Caeseele, Gregory Hammond, Carol Kurbis, Tim Hilderman, and Lawrence Elliott
, Paul Van Caeseele, Gregory Hammond, Carol Kurbis, Tim Hilderman, and Lawrence Elliott
Table 6
Demographic and clinical characteristics of case-patients and controls in a study of the association between the 2008–09 TIV and influenza A(H1N1)pdm09 virus infection, Manitoba, Canada, 2009*
| Characteristic | No (%) study participants, by age group, y |
|||||
|---|---|---|---|---|---|---|
| <12 | 12–19 | 20–34 | 35–44 | 45–64 | >65 | |
| Community controls | ||||||
| Total | 381 (15.4) | 242 (9.8) | 553 (22.3) | 384 (15.5) | 638 (25.7) | 281 (11.3) |
| Female sex | 185 (48.6) | 138 (57.0) | 353 (63.8) | 237 (61.7) | 385 (60.3) | 170 (60.5) |
| Chronic disease | 30 (7.9) | 21 (8.7) | 57 (10.3) | 74 (19.3) | 203 (31.8) | 163 (58.0) |
| Receipt of 2007–08 TIV | 34 (8.9) | 19 (7.9) | 76 (13.7) | 67 (17.4) | 187 (29.3) | 161 (57.3) |
| Receipt of 2008–09 TIV | 53 (13.9) | 20 (8.3) | 80 (14.5) | 72 (18.8) | 179 (28.1) | 160 (56.9) |
| Community case-patients | ||||||
| Total | 180 (28.8) | 105 (16.8) | 154 (24.6) | 76 (12.1) | 102 (16.3) | 9 (1.4) |
| Female sex | 88 (48.9) | 50 (47.6) | 81 (52.6) | 39 (51.3) | 58 (56.9) | 6 (66.7) |
| Chronic disease | 9 (5.0) | 15 (14.3) | 17 (11.0) | 13 (17.1) | 29 (28.4) | 7 (77.8) |
| Receipt of 2007–08 TIV | 26 (14.4) | 9 (8.6) | 24 (15.6) | 21 (27.6) | 35 (34.3) | 8 (88.9) |
| Receipt of 2008–09 TIV | 24 (13.3) | 10 (9.5) | 20 (13.0) | 15 (19.7) | 34 (33.3) | 6 (66.7) |
| Hospitalized case-patients | ||||||
| Total | 68 (33.2) | 21 (10.2) | 44 (21.5) | 25 (12.2) | 37 (18.0) | 10 (4.9) |
| Female sex | 23 (33.8) | 13 (61.9) | 32 (72.7) | 12 (48.0) | 27 (73.0) | 8 (80.0) |
| Chronic disease | 17 (25.0) | 5 (23.8) | 10 (22.7) | 13 (52.0) | 25 (67.6) | 8 (80.0) |
| Receipt of 2007–08 TIV | 6 (8.8) | 0 (0.0) | 4 (9.1) | 9 (36.0) | 12 (32.4) | 6 (60.0) |
| Receipt of 2008–09 TIV | 9 (13.2) | 3 (14.3) | 4 (9.1) | 5 (20.0) | 14 (37.8) | 4 (40.0) |
*TIV, inactivated trivalent influenza vaccine.
Page created: April 05, 2012
Page updated: April 05, 2012
Page reviewed: April 05, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.